Please ensure Javascript is enabled for purposes of website accessibility

Here's Why CRISPR Therapeutics AG Gained as Much as 14% Today

By Maxx Chatsko - Updated Mar 10, 2018 at 11:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The gene-editing pioneer announced full-year 2017 results and issued a business update.

What happened

Shares of gene-editing pioneer CRISPR Therapeutics AG (CRSP 1.55%) gained 14% today after the company announced full-year 2017 earnings and provided shareholders with a business update for what to expect in the year ahead. In the fourth quarter of 2017, the company called in a giant chunk of deferred revenue from its collaboration with Vertex to bring its full-year 2017 revenue total to $41 million. That was a nice surprise for a pre-clinical company.

More importantly, CRISPR Therapeutics and Vertex are advancing toward the clinic in 2018 and plan to initiate their first trials in blood diseases, including transfusion-dependent beta-thalassemia patients and those with sickle cell disease.

As of 2:33 p.m. EST, the stock had settled to a 11.4% gain.

A woman pumping her fist while checking her smartphone as $20 and $50 bills falls around her.

Image source: Getty Images.

So what

The last few years have been characterized by a lot of talk about what CRISPR gene-editing technologies could mean for the future of medicine. This year, that talk will finally turn to action as the big three CRISPR gene-editing companies -- CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics -- jump into their first ever clinical trials. Even Sangamo Therapeutics, a pioneer in zinc finger nuclease, has begun testing its approach to gene editing in the clinic.

Together with Vertex, CRISPR Therapeutics is using CRISPR gene editing to engineer blood stem cells and correct mutations that cause symptoms in patients with blood diseases. Considering that several of these diseases are caused by "simple" genetic mutations, they're excellent targets for early versions of the technology. Several academic studies have even hinted that sickle cell disease could be cured using CRISPR, but investors shouldn't jump to any conclusions just yet.

Now what

All three major CRISPR stocks have been on fire in recent months as investors eagerly look forward to clinical studies providing meaningful catalysts. While the future potential of gene-editing technology is incredible, it may be valuable to consider whether or not expectations are outpacing real-world results. If early drug candidates stumble in regulated studies, it could come back to sting shareholders enjoying the ride up at the moment.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
CRSP
$78.66 (1.55%) $1.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.